In a retrospective analysis of the Optum database, overactive bladder patients treated with mirabegron bladder patients persisted longer with treatment than patients treated with tolterodine, and had reduced resource utilization and costs.
Alan Fan, MPharm
Advertisement
Articles by Alan Fan, MPharm
Advertisement
Latest Updated Articles
- Persistence With Mirabegron Versus Tolterodine in Patients With Overactive Bladder
Published: April 19th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Common Virus May Hold New Clues to Lupus
2
Zongertinib Shows Clinically Meaningful Efficacy in Advanced HER2-Mutant NSCLC
3
Expert Discusses Logistical Considerations and Future Research Needs for Radiopharmaceuticals
4
SHR-A1811 Plus Pertuzumab Improves Survival in HER2-Positive Metastatic Breast Cancer
5
